Document Detail


Patient reported outcomes in benign multiple sclerosis.
MedLine Citation:
PMID:  21372114     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background: Benign MS patients have a mild course of disease and show no or minimal accumulation of disability over time. Little is known about the patient reported outcomes (PROs) in benign MS. Objective: The objective of the study was to compare PROs in benign MS patients and patients with similar disease duration or disability status, and to investigate how the definition of benign MS affected this outcome. Methods: Two groups of Benign MS patients (disease duration ≥15 years, Expanded Disability Status Scale [EDSS] score ≤1.5 [Benign-1.5], or ≤3.0 [Benign-3]) were compared with four other MS groups: disease duration ≥15 years, EDSS score >3.0 (Late-MS); disease duration <15 years, and EDSS score ≤1.5 (Low-EDSS-1.5), or ≤3.0 (Low-EDSS-3); disease duration ≤5 years (Early-MS). PROs included measures of QOL, fatigue, depression, and social support. Cognitive function was also assessed. Results: Both benign groups had better PROs than Late MS patients on all measures (p < 0.05). QOL, depression, and fatigue were significantly different between Benign-1.5 and Early-MS groups (p < 0.01). Benign-1.5 had higher mental health QOL than Low EDSS-1.5, but was otherwise similar. Benign-3 patients had worse depression than Early-MS (p < 0.01), and worse cognition compared with Low-EDSS-3 (p = 0.033). Benign-1.5 had higher QOL and lower fatigue (p < 0.005) than Benign-2-3, and showed a marginally significant difference in cognitive functioning (p = 0.055). Conclusions: Patients with benign MS had better PROs than other groups of MS patients, suggesting that both disease duration and disability influence PROs. The study also showed a difference in PROs based on the way benign MS was defined.
Authors:
Line E Hviid; Brian C Healy; David J Rintell; Tanuja Chitnis; Howard L Weiner; Bonnie I Glanz
Related Documents :
21274364 - Switching from oral donepezil to rivastigmine transdermal patch in alzheimer's disease:...
19826364 - Other paradigms: randomized discontinuation trial design.
21369494 - Validation of new symptom-based fibromyalgia criteria for irritable bowel syndrome co-m...
21143564 - Prognostic value of depressive symptoms on mortality, morbidity and nursing home admiss...
2038534 - Comparison of two locus of control scales in predicting relapse in an alcoholic populat...
9789824 - Cholinergic foundations of alzheimer's disease therapy.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-3
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  -     ISSN:  1477-0970     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Partners Multiple Sclerosis Center, Brigham and Women's Hospital/ Harvard Medical Institute, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment.
Next Document:  Olfactory threshold is impaired in early, active multiple sclerosis.